Profile data is unavailable for this security.
About the company
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
- Revenue in AUD (TTM)14.46m
- Net income in AUD-709.00k
- Incorporated1998
- Employees43.00
- LocationAcrux Ltd103-113 Stanley St, West MelbourneMELBOURNE 3003AustraliaAUS
- Phone+61 38379-0100
- Fax+61 38379-0101
- Websitehttps://www.acrux.com.au/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argent BioPharma Ltd | 1.32m | -17.02m | 16.75m | -- | -- | 9.96 | -- | 12.65 | -3.32 | -3.32 | 0.1003 | 0.0372 | 0.0813 | 0.7078 | 1.58 | -- | -105.32 | -111.29 | -345.98 | -171.05 | 21.87 | 32.52 | -1,295.20 | -632.42 | 0.6561 | -24.85 | 0.4104 | -- | -28.41 | 47.31 | -2.34 | -- | -16.20 | -- |
| Rhythm Biosciences Ltd | 157.67k | -8.63m | 17.65m | -- | -- | 12.90 | -- | 111.95 | -0.0386 | -0.0386 | 0.0007 | 0.0055 | 0.0263 | -- | 1.81 | -- | -144.00 | -106.11 | -169.71 | -125.51 | -1,899.74 | -1,210.71 | -5,473.20 | -6,642.26 | 2.04 | -- | 0.0304 | -- | 814.18 | 28.77 | 6.55 | -- | -20.43 | -- |
| Auscann Group Holdings Ltd | 2.05m | -9.44m | 17.76m | 27.00 | -- | -- | -- | 8.67 | -0.0213 | -0.0217 | 0.0043 | 0.0162 | 0.1674 | -- | 5.35 | -- | -77.15 | -39.85 | -78.72 | -40.73 | 100.59 | -- | -460.74 | -925.91 | -- | -23.16 | 0.00 | -- | 13.88 | 51.37 | 57.10 | -- | -- | -- |
| Lumos Diagnostics Holdings Ltd | 12.39m | -13.30m | 17.81m | -- | -- | 1.28 | -- | 1.44 | -0.0357 | -0.0357 | 0.0352 | 0.0289 | 0.3418 | 2.24 | 6.37 | -- | -36.70 | -40.15 | -55.14 | -56.67 | 59.73 | 45.97 | -107.38 | -162.90 | 0.479 | -6.25 | 0.4803 | -- | -9.42 | 39.29 | 80.38 | -- | -38.50 | -- |
| Algorae Pharmaceuticals Ltd | 84.10k | -2.25m | 18.56m | -- | -- | 5.12 | -- | 220.71 | -0.0015 | -0.0015 | 0.00006 | 0.0022 | 0.0245 | -- | 1.79 | -- | -65.51 | -46.12 | -70.91 | -53.52 | -- | -- | -2,678.04 | -591.05 | -- | -136.75 | 0.00 | -- | 1,132.26 | -44.06 | -7.68 | -- | -- | -- |
| LBT Innovations Limited | 2.00m | -21.38m | 18.77m | 17.00 | -- | 6.91 | -- | 9.37 | -0.0428 | -0.0428 | 0.0038 | 0.002 | 0.1087 | 0.0819 | 2.25 | 117,882.40 | -115.89 | -28.85 | -131.86 | -30.99 | 94.76 | -- | -1,066.62 | -441.76 | 3.30 | -6.85 | 0.5633 | -- | -5.29 | -18.45 | -239.17 | -- | -34.63 | -- |
| Amplia Therapeutics Ltd | 1.87m | -4.46m | 19.01m | 1.00 | -- | 0.9472 | -- | 10.18 | -0.0224 | -0.0224 | 0.0094 | 0.0739 | 0.0949 | -- | 0.7018 | -- | -22.64 | -25.27 | -26.24 | -26.78 | -- | -- | -238.69 | -342.26 | -- | -- | 0.1318 | -- | -42.10 | 12.31 | -71.30 | -- | 31.88 | -- |
| Immuron Ltd | 3.58m | -3.88m | 21.43m | 6.00 | -- | 1.22 | -- | 5.99 | -0.017 | -0.017 | 0.0157 | 0.0769 | 0.1664 | 0.6468 | 7.92 | 596,106.70 | -18.06 | -27.48 | -19.86 | -29.58 | 80.87 | 77.52 | -108.52 | -296.64 | 7.79 | -2.85 | 0.0023 | -- | 135.85 | -13.34 | -32.66 | -- | 3.27 | -- |
| BPH Energy Ltd | 345.67k | 894.65k | 22.95m | 2.00k | 20.41 | 0.9868 | -- | 66.40 | 0.001 | 0.001 | 0.0004 | 0.0203 | 0.0177 | -- | 5.97 | -- | 4.58 | -6.89 | 4.78 | -7.72 | 56.39 | -- | 258.50 | -357.76 | -- | -- | 0.0043 | -- | 96.54 | 5.21 | 179.13 | -- | -- | -- |
| Noxopharm Ltd | 3.90m | -12.13m | 23.38m | 1.00k | -- | 3.56 | -- | 5.99 | -0.0415 | -0.0415 | 0.0134 | 0.0225 | 0.2684 | -- | 1.64 | 3,901.84 | -83.43 | -50.96 | -94.78 | -62.98 | -- | -- | -310.82 | -191.70 | -- | -1.47 | 0.00 | -- | 11.32 | 44.02 | 19.34 | -- | -- | -- |
| Acrux Ltd | 14.46m | -709.00k | 23.55m | 43.00 | -- | 4.16 | -- | 1.63 | -0.0024 | -0.0024 | 0.0502 | 0.0195 | 1.29 | -- | 4.86 | -- | -6.34 | -39.91 | -9.21 | -46.00 | 72.38 | -- | -4.90 | -132.53 | -- | -- | 0.2861 | -- | 133.74 | 28.29 | 92.23 | -- | -16.66 | -- |
| Syntara Ltd | 9.83m | -14.26m | 23.88m | 107.00 | -- | 2.65 | -- | 2.43 | -0.0197 | -0.0172 | 0.0136 | 0.0075 | 0.442 | 1.58 | 2.22 | -- | -64.13 | -27.33 | -97.76 | -34.23 | 81.69 | 88.37 | -145.11 | -61.99 | 1.75 | -262.59 | 0.0674 | -- | 23.60 | -18.30 | -486.78 | -- | -31.06 | -- |
| Tryptamine Therapeutics Ltd | 1.21m | -4.32m | 25.05m | -- | -- | 3.72 | -- | 20.75 | -0.0162 | -0.0162 | 0.0037 | 0.0062 | 0.2368 | -- | -- | -- | -84.69 | -66.34 | -120.26 | -79.70 | -- | -- | -357.70 | -228.11 | -- | -21.62 | 0.00 | -- | -18.97 | 138.73 | 29.29 | -- | 68.45 | -- |
| Alterity Therapeutics Ltd | 123.46k | -12.28m | 26.23m | 11.00 | -- | 0.7951 | -- | 212.42 | -0.005 | -0.005 | 0.00005 | 0.0063 | 0.0044 | -- | 1.52 | 11,223.64 | -44.20 | -53.02 | -53.57 | -61.96 | -- | -- | -9,947.97 | -40,995.62 | -- | -- | 0.0143 | -- | 557.60 | -39.40 | -7.47 | -- | -34.88 | -- |
| Cann Group Ltd | 16.45m | -29.28m | 27.12m | 40.00 | -- | 0.5339 | -- | 1.65 | -0.0724 | -0.0724 | 0.0406 | 0.1161 | 0.1237 | 0.3952 | 7.37 | -- | -22.03 | -22.28 | -34.23 | -24.43 | 21.11 | -- | -178.07 | -407.57 | 0.0861 | -5.88 | 0.5646 | -- | 114.90 | 89.76 | -27.66 | -- | -11.16 | -- |
Data as of Jun 04 2024. Currency figures normalised to Acrux Ltd's reporting currency: Australian Dollar AUD
